Compare Stryker Corporation (SYK) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs TORM plc — how do they compare? Stryker Corporation trades at $276.85 (market cap $106.24B), while TORM plc trades at $40.01 (market cap $4.12B). The key difference: Stryker Corporation is far larger — about 25.8× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and TORM plc for 23 Days on average.
| SYK | TRMD | |
|---|---|---|
Market Cap | $106.24B | $4.12B |
Volume | 2,982,001 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $388.35 | $41.05 |
52-Week Low | $269.75 | $19.39 |
Typical Hold Time | 20 Days | 23 Days |
Enterprise Value | $117.70B | $4.83B |
Dividend Yield | 1.27% | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
TRMD trades at $38.92, down 0.33% on the day, with strong technical momentum showing a bullish moving average signal despite RSI_6 indicating potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 35.52% net income margin and attractive valuation metrics including a 6.59 P/E ratio. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates.
The outlook remains positive with 100% analyst buy ratings and improving cash flow projections for 2026. Key risks include spot rate volatility in the tanker market and recent insider selling activity. The stock offers value characteristics with strong dividend potential but faces near-term headwinds from declining contracted rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
